Kalciumkanalhämmare riskabel medicin?: Dålig uppföljning trots tidig varning

Lakartidningen

Volumn 93, Issue 15, 1996, Pages 1440-1444

  Werkö, Lars ^a  

^a Tidigare Forskningschef vid Astra ^*

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT;

ARTICLE; CLINICAL TRIAL; FOLLOW UP; HUMAN; RISK FACTOR;

CALCIUM CHANNEL BLOCKERS; CLINICAL TRIALS; FOLLOW-UP STUDIES; HUMANS; RISK FACTORS;

EID: 0030577913     PISSN: 00237205     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Carlsson G, Arvidsson O, Bygren LO, Werkö L. Liv och hälsa. Stockholm. Liber, 1979: 130.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine, dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
3. Psaty BM, Heckbert SR, Koepsall TD, Siskovick DS, Raghunalhan TE, Weiss NS et al. The risk of myocardial infarction associated with anti-hypertensive drug therapies. JAMA 1995; 274: 620-5.
4. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonon P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7.
5. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995; 92: 1074-88
6. Yusuf S. Calciumantagonists in coronary artery disease and hypertension. Time for reevaluation? Circulation 1995; 92: 1079-82.
7. Opie LH, Messerli FH. Nifedipine and mortality. Grave defects in the dossier. Circulation 1995; 92: 1068-73.
8. Messerli FH, MacDonald G, Poole-Wilson PA, Brown MJ, Horton R. Are calcium antagonists safe? Lancet 1995; 346: 767-70.
9. Elliott HL, Epstein M, Haller M, Mancia G. Safety of calcium antagonists. Lancet 1995; 346: 1421.
10. HINT research group. Early treatment of unstable angina in the coronary care unit: a randomized, double blind, placebo controlled comparison of recurrent ischemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400-15.
11. Lichtlen PR, Hugenholtz PG, Raffenbeul W, Hecket H, Jost S, Deckers JW, for the INTACT study group. Retardation of angiographie progression of coronary artery disease by nifedipine: results of the INTACT. Lancet 1990; 335: 1109-13.
12. Verheugt FWA, Goldstein MR, Bajaj R, Azizi M, Chatellier G, Lichtlen PR. Nifedipine and coronary artery disease. (Letter to the editor.) Lancet 1990; 336: 172-4.
13. Schubert T, Opie LH, Cooper RS, Collins R, Peto R, Lichtlen PR. Risks and benefits of calcium antagonists. (Letter to the editor.) Lancet 1995; 346: 961-2.
14. Vanhoutte PM, Paoletti R, Govoni S, eds. Calcium antagonists, pharmacology and clinical research. Ann NY Acad Sci 1988; 522.
15. National Heart, Lung, and Blood Institute, PHS, Dept of Health and Human Services. New analyses regarding the safety of calcium channel blockers: a statement for health professionals from the NHLBI. New York: NHLBI, 1995, Aug 31.
16. Sasich LD, Wolfe SM, Lurie P. Citizens' petition to require a warning on all calcium channel blocking drugs. Public Citizen, letter to PDA Commissioner, Nov 9 1995.
17. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995; 346: 586-7.